BRPI0919526A2 - derivado de ciclo-hexano, produto farmacêutico, analgésico, e, droga terapêutica para dor neuropática e/ou dor nociceptiva - Google Patents
derivado de ciclo-hexano, produto farmacêutico, analgésico, e, droga terapêutica para dor neuropática e/ou dor nociceptivaInfo
- Publication number
- BRPI0919526A2 BRPI0919526A2 BRPI0919526A BRPI0919526A BRPI0919526A2 BR PI0919526 A2 BRPI0919526 A2 BR PI0919526A2 BR PI0919526 A BRPI0919526 A BR PI0919526A BR PI0919526 A BRPI0919526 A BR PI0919526A BR PI0919526 A2 BRPI0919526 A2 BR PI0919526A2
- Authority
- BR
- Brazil
- Prior art keywords
- pain
- analgesic
- pharmaceutical
- therapeutic drug
- cyclohexane derivative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008281258 | 2008-10-31 | ||
| JP2008-281258 | 2008-10-31 | ||
| JP2009-176619 | 2009-07-29 | ||
| JP2009176619 | 2009-07-29 | ||
| PCT/JP2009/068644 WO2010050577A1 (ja) | 2008-10-31 | 2009-10-30 | シクロヘキサン誘導体及びその医薬用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0919526A2 true BRPI0919526A2 (pt) | 2015-12-08 |
| BRPI0919526B1 BRPI0919526B1 (pt) | 2020-03-17 |
| BRPI0919526B8 BRPI0919526B8 (pt) | 2021-05-25 |
Family
ID=42128936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0919526A BRPI0919526B8 (pt) | 2008-10-31 | 2009-10-30 | derivado de ciclo-hexano, e, produto farmacêutico |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US8247569B2 (pt) |
| EP (1) | EP2341047B1 (pt) |
| JP (1) | JP5522031B2 (pt) |
| KR (1) | KR101313658B1 (pt) |
| CN (1) | CN102203068B (pt) |
| AU (1) | AU2009310807B2 (pt) |
| BR (1) | BRPI0919526B8 (pt) |
| CA (1) | CA2739883C (pt) |
| DK (1) | DK2341047T3 (pt) |
| ES (1) | ES2525708T3 (pt) |
| MX (1) | MX2011004576A (pt) |
| PL (1) | PL2341047T3 (pt) |
| PT (1) | PT2341047E (pt) |
| RU (1) | RU2478621C2 (pt) |
| TW (1) | TWI435874B (pt) |
| WO (1) | WO2010050577A1 (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012022944B1 (pt) * | 2010-03-31 | 2021-08-31 | Toray Industries, Inc | Agente terapêutico ou agente profilático |
| EP2554541B1 (en) * | 2010-03-31 | 2015-12-09 | Toray Industries, Inc. | Therapeutic agent or prophylactic agent for fibromyalgia |
| BR122021002784B1 (pt) * | 2010-04-28 | 2021-08-31 | Toray Industries, Inc | Agente terapêutico ou agente profilático para a doença de alzheimer |
| WO2012015027A1 (ja) * | 2010-07-30 | 2012-02-02 | 東レ株式会社 | 神経障害性疼痛の治療剤又は予防剤 |
| WO2015089192A1 (en) * | 2013-12-11 | 2015-06-18 | Quanticel Pharmaceuticals, Inc. | Inhibitors of lysine specific demethylase-1 |
| BR112016016674A2 (pt) * | 2014-01-29 | 2017-08-08 | Toray Industries | Agente terapêutico ou profilático para uso no tratamento de esclerose múltipla |
| SI3137169T1 (sl) | 2014-05-01 | 2022-04-29 | Celgene Quanticel Research, Inc. | Inhibitorji lizin specifične demetilaze-1 |
| WO2018181859A1 (ja) * | 2017-03-31 | 2018-10-04 | 東レ株式会社 | 抗がん剤誘発末梢神経障害の治療剤又は予防剤 |
| CN115521190A (zh) * | 2022-09-20 | 2022-12-27 | 阜阳欣奕华制药科技有限公司 | 乙炔基环己醇的制备方法及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6058981A (ja) * | 1983-09-09 | 1985-04-05 | Takeda Chem Ind Ltd | ５−ピリジル−１，３−チアゾ−ル誘導体，その製造法およびそれを含んでなる医薬組成物 |
| EP0149884B1 (en) * | 1983-09-09 | 1992-12-16 | Takeda Chemical Industries, Ltd. | 5-pyridyl-1,3-thiazole derivatives, their production and use |
| CN1046714C (zh) * | 1993-12-20 | 1999-11-24 | 藤泽药品工业株式会社 | 二芳基噁唑衍生物及其制法、应用和药物组合物 |
| GB9713726D0 (en) * | 1997-06-30 | 1997-09-03 | Ciba Geigy Ag | Organic compounds |
| JPH11193281A (ja) * | 1997-10-27 | 1999-07-21 | Takeda Chem Ind Ltd | アデノシンａ３受容体拮抗剤およびチアゾール化合物 |
| AU4308300A (en) | 1999-05-03 | 2000-11-17 | Dr. Reddy's Research Foundation | Pyrazoles having antiinflammatory activity |
| RU2005120779A (ru) * | 2002-12-02 | 2006-01-20 | Фудзисава Фармасьютикал Ко., Лтд. (JP) | Производные пиразола |
| AU2002953019A0 (en) * | 2002-12-02 | 2002-12-12 | Fujisawa Pharmaceutical Co., Ltd. | Azole derivatives |
| ES2379076T3 (es) | 2002-12-02 | 2012-04-20 | Astellas Pharma Inc. | Derivados de pirazol útiles como inhibidores de COX-I |
| JP2007197324A (ja) * | 2006-01-23 | 2007-08-09 | Toray Ind Inc | ２，４，５−置換−１，３−アゾール誘導体 |
| CN101454299A (zh) | 2006-03-27 | 2009-06-10 | 东丽株式会社 | 酰脲衍生物及其医药用途 |
| WO2008105383A1 (ja) * | 2007-02-26 | 2008-09-04 | Toray Industries, Inc. | ピラゾール誘導体およびその医薬用途 |
-
2009
- 2009-10-29 TW TW098136604A patent/TWI435874B/zh not_active IP Right Cessation
- 2009-10-30 BR BRPI0919526A patent/BRPI0919526B8/pt active IP Right Grant
- 2009-10-30 ES ES09823687.0T patent/ES2525708T3/es active Active
- 2009-10-30 WO PCT/JP2009/068644 patent/WO2010050577A1/ja active Application Filing
- 2009-10-30 RU RU2011121809/04A patent/RU2478621C2/ru not_active IP Right Cessation
- 2009-10-30 DK DK09823687.0T patent/DK2341047T3/en active
- 2009-10-30 US US13/126,901 patent/US8247569B2/en active Active
- 2009-10-30 KR KR1020117009913A patent/KR101313658B1/ko active IP Right Grant
- 2009-10-30 AU AU2009310807A patent/AU2009310807B2/en not_active Ceased
- 2009-10-30 CA CA2739883A patent/CA2739883C/en active Active
- 2009-10-30 CN CN200980143945.6A patent/CN102203068B/zh active Active
- 2009-10-30 PL PL09823687T patent/PL2341047T3/pl unknown
- 2009-10-30 PT PT98236870T patent/PT2341047E/pt unknown
- 2009-10-30 EP EP09823687.0A patent/EP2341047B1/en active Active
- 2009-10-30 MX MX2011004576A patent/MX2011004576A/es active IP Right Grant
- 2009-10-30 JP JP2010502106A patent/JP5522031B2/ja active Active
-
2012
- 2012-06-27 US US13/534,093 patent/US8349874B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20110067053A (ko) | 2011-06-20 |
| US20110201650A1 (en) | 2011-08-18 |
| EP2341047A4 (en) | 2012-08-29 |
| MX2011004576A (es) | 2011-06-17 |
| AU2009310807B2 (en) | 2012-02-23 |
| BRPI0919526B8 (pt) | 2021-05-25 |
| JP5522031B2 (ja) | 2014-06-18 |
| EP2341047A1 (en) | 2011-07-06 |
| WO2010050577A1 (ja) | 2010-05-06 |
| US8349874B2 (en) | 2013-01-08 |
| KR101313658B1 (ko) | 2013-10-02 |
| DK2341047T3 (en) | 2015-01-19 |
| CA2739883A1 (en) | 2010-05-06 |
| RU2478621C2 (ru) | 2013-04-10 |
| ES2525708T3 (es) | 2014-12-29 |
| TWI435874B (zh) | 2014-05-01 |
| US8247569B2 (en) | 2012-08-21 |
| CA2739883C (en) | 2013-05-28 |
| US20120270906A1 (en) | 2012-10-25 |
| JPWO2010050577A1 (ja) | 2012-03-29 |
| RU2011121809A (ru) | 2012-12-10 |
| EP2341047B1 (en) | 2014-10-15 |
| BRPI0919526B1 (pt) | 2020-03-17 |
| CN102203068B (zh) | 2014-03-19 |
| PL2341047T3 (pl) | 2015-03-31 |
| CN102203068A (zh) | 2011-09-28 |
| PT2341047E (pt) | 2015-01-14 |
| TW201022226A (en) | 2010-06-16 |
| AU2009310807A1 (en) | 2010-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0919526A2 (pt) | derivado de ciclo-hexano, produto farmacêutico, analgésico, e, droga terapêutica para dor neuropática e/ou dor nociceptiva | |
| BRPI1007636A2 (pt) | Composição farmacêutica, forma de dosagem, método para a preparação da composição farmacêutica, método de preparação da forma de dosagem e método de tratamento da dor | |
| DK2274032T3 (da) | Anordning til medicinindgivelse | |
| BRPI1009324A2 (pt) | compostos e/ou farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e respectivos usos | |
| BR112013014583A2 (pt) | composição farmacêutica, e, métodos para o tratamento de inflamação, para o tratamento da dor, e para preparar 3-metanossulfonilpropionitrila | |
| BR112012031836A2 (pt) | combinação farmacêutica para o tratamento da dor | |
| CY2016053I1 (el) | Μεθοδοι αγωγης χρησιμοποιωντας φαρμακευτικες ουσιες συλληψης αμμωνιας | |
| DK2083889T3 (da) | Doserings- og drivmekanisme til lægemiddeladministrationsanordning | |
| BRPI0807544A2 (pt) | Sólido farmacêutico e dose de vacina | |
| BR112012022211A2 (pt) | composto. composição farmacêutica, método de tratamento de uma doença meidada por h4r, método de inibição de h4h, método de tratamento da dor ou inflamação resultante de cirurgia de catarata, método para atingir um efeito em um paciente e uso de uma composto | |
| BR112013013525A2 (pt) | formulação de liberação controlada sólida de lacosamida para administração oral, composição farmacêutica sólida, e, método para a prevenção, alívio e/ou tratamento de uma doença do sistema nervoso central | |
| BRPI1010861A2 (pt) | métodos para tratamento de dor, inflamação ou osteoartrite, pacote e formulação farmacêutica | |
| BR112012013589A2 (pt) | dispositivo e método para envio de dois ou mais agentes de fármaco | |
| IL193727A0 (en) | Dosage forms for administering combinations of drugs | |
| BRPI0821876A2 (pt) | Sistemas e métodos para administração de medicação | |
| BRPI0913214A2 (pt) | sistema de fornecimento de drogas transdérmico estabilizado | |
| DK2381988T3 (da) | Medikamentadministrationsanordning | |
| DK2299977T3 (da) | Liposomer til lægemiddelafgivelse og fremgangsmåder til fremstilling heraf | |
| LTPA2019508I1 (lt) | Vaistų pristatymo sistema, skirta sunkiai vandenyje tirpstančių, farmaciškai aktyvių medžiagų, pateikimui | |
| BRPI0910740A2 (pt) | sistema terapêutico transdérmico para a administração de fentanila ou um análogo da mesma | |
| BRPI0920658A2 (pt) | dispositivo de inalação e método de dispensar medicamento | |
| BR112012005629A2 (pt) | sistema terapêutico transdérmico para administrar fentanila ou um análogo da mesma | |
| BRPI1007474A2 (pt) | formulação para administração por via transmucosa oral de moléculas antálgicas e/ou antiespasmódicos. | |
| ZA201203281B (en) | Pharmaceutical combinations, pharmaceutical compositions, medicament and method for the treatment of animals | |
| BRPI0918539A2 (pt) | preparação farmacêutica sólida para administração oral |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07D 231/12 , A61K 31/415 , A61K 31/421 , A61K 31/426 , A61K 31/4439 , A61P 25/04 , A61P 29/02 , C07D 263/32 , C07D 277/24 , C07D 401/04 Ipc: A61K 31/415 (1974.07), A61K 31/4439 (2000.01), A61 |
|
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/03/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/10/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |